Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Protein or biologic · Protein or protein analogue
Detailed molecular class: Recombinant protein hormone
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Growth-hormone receptor agonism and IGF-1 effects.
Evidence and critical reading
Reported scientific and empirical uses
GH/IGF hormonal axis · Reported muscle and performance
Recombinant protein hormone with products for GH deficiency/defined growth disorders.
Human evidence
US label supports defined pediatric growth disorders and adult growth-hormone deficiency.
Preclinical evidence
Approved therapeutic indications must be distinguished from general anti-aging claims.
Critical reading and limitations
Efficacy for deficiency is not rejuvenation evidence in adults with a normal axis.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
US: approved Genotropin product for specified indications; this does not approve catalog HGH.
Adverse effects and unknowns
Label contraindications include active malignancy, acute critical illness and hypersensitivity; glucose intolerance and fluid retention matter. Glucocorticoids and diabetes medicines require product-specific interaction review.
Label: active malignancy/acute critical illness are contraindications; glucose/fluid retention matter.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Somatropin · 818 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT00663611 · Growth Hormone Administration and the Human Immune SystemRegistry status: CompletedLast update posted: October 16, 2026Query verification: October 16, 2026
NCT06103513 · Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in ChildrenRegistry status: RecruitingLast update posted: October 13, 2026Query verification: October 16, 2026
NCT04867317 · Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)Registry status: RecruitingLast update posted: October 13, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- REG-GH
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026